20th anniversary of adjuvant trastuzumab: reflections on a breakthrough moment.

Twenty years after its initial approval, trastuzumab remains a cornerstone in the treatment of patients with human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (eBC). Long-term follow-up from pivotal adjuvant trials has con…

Preview only. Read the full abstract at the source